Antibodies that bind to two targets are an established way of treating the blood cancer multiple myeloma. Aiming to top those medicines, AbbVie has secured rights to an early-clinical drug that works ...

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature ...

Cancer treatment resistance is one of the biggest challenges in cancer care. It occurs when cancer cells adapt to survive despite therapy, making treatments less effective or even completely ...

File photo: — Patient Receives Chemotherapy. Source - National Cancer Institute/ Rhoda Baer (Photographer). Public Domain — CC0 1.0 Universal File photo: — Patient Receives Chemotherapy. Source - ...

Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors learning to shrug off chemotherapy that once held them in check. A new wave of ...

Ovarian cancer treatment faces challenges with high relapse and drug resistance rates, despite initial chemotherapy effectiveness. Cytokines like IL-6 and IL-11 are associated with complex tumor ...

Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites seeding new resistant tumors elsewhere in the body. Combating the problem has ...

Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical giant ...

WILMINGTON, DEL. (November 14, 2025) – In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology ...

Biologists have uncovered a new mode of communication inside cells that helps bacterial pathogens learn how to evade drugs.